IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11827628 B1

PDFFull Text
Date of Patent:
Nov. 28, 2023

Filed:

Nov. 02, 2021

Compositions and methods for inhibition of the jak pathway

Applicant:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Hui Li, Santa Clara, CA (US);

Sambaiah Thota, Union City, CA (US);

David Carroll, San Francisco, CA (US);

Ankush Argade, Foster City, CA (US);

Kin Tso, San Francisco, CA (US);

Arvinder Sran, Fremont, CA (US);

Jeffrey Clough, Watsonville, CA (US);

Holger Keim, Newbury Park, CA (US);

Somasekhar Bhamidipati, Foster City, CA (US);

Vanessa Taylor, San Francisco, CA (US);

Robin Cooper, St. George Island, FL (US);

Rajinder Singh, Belmont, CA (US);

Brian Wong, Los Altos, CA (US);

Assignee:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorneys:

Travis Young

Bozicevic, Field & Francis LLP

Primary Examiner:

Deepak R Rao

Int. Cl.
CPC ...
C07D 413/12 (2006.01); C07D 403/04 (2006.01); C07D 239/42 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 413/14 (2006.01); C07D 239/48 (2006.01); A61K 31/343 (2006.01); A61K 31/436 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/5383 (2006.01); A61K 31/541 (2006.01); A61K 31/695 (2006.01); A61K 38/13 (2006.01); A61K 39/395 (2006.01); C07D 498/04 (2006.01); C07F 7/10 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 417/12 (2006.01); C07F 7/08 (2006.01); C07D 285/22 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 31/343 (2013.01); A61K 31/436 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/538 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/541 (2013.01); A61K 31/695 (2013.01); A61K 38/13 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 239/42 (2013.01); C07D 239/48 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 498/04 (2013.01); C07F 7/0812 (2013.01); C07F 7/10 (2013.01); C07D 285/22 (2013.01);
Abstract

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Find Patent Forward Citations

Loading…